23:55 , Nov 14, 2018 |  BC Extra  |  Politics & Policy

Michigan to begin talks with drug manufacturers for value-based deals

With a stamp of approval from CMS on Wednesday, Michigan joins Oklahoma as one of the only two states with the agency's OK to negotiate Medicaid outcomes-based pricing agreements with drug manufacturers. "Michigan’s waiver will...
19:23 , Oct 26, 2018 |  BC Week In Review  |  Financial News

89Bio, a NASH start-up with Teva ties, debuts with $60M

89Bio Ltd. (San Francisco, Calif.) will use its $60 million series A financing to develop therapeutics for non-alcoholic steatohepatitis and other liver and metabolic diseases. The financing was co-led by OrbiMed Israel, OrbiMed US and...
22:52 , Oct 25, 2018 |  BC Extra  |  Financial News

89Bio, a NASH start-up with Teva ties, debuts with $60M

89Bio Ltd. (San Francisco, Calif.) will use its $60 million series A financing to develop therapeutics for non-alcoholic steatohepatitis and other liver and metabolic diseases. The financing was co-led by OrbiMed Israel, OrbiMed US and...
02:50 , Oct 20, 2018 |  BioCentury  |  Product Development

New shops for value-based deals

Value-based payment models are starting to appear beyond the high-profile insurers and PBMs that have dominated the scene, with a series of deals struck since August by the Oklahoma Health Care Authority and the University...
18:13 , Oct 12, 2018 |  BC Week In Review  |  Company News

Otsuka, Proteus to develop additional digital medicine systems

Proteus Digital Health Inc. (Redwood City, Calif.) and Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) expanded their collaboration to develop and commercialize additional digital medicines over the next five years. Otsuka paid Proteus $88 million in...
01:19 , Oct 6, 2018 |  BioCentury  |  Finance

In sight of uncharted territory

Strong growth from small- and mid-caps coupled with a late run from large cap biotechs has pushed the sector within sight of its all-time high in 2015. Some buysiders now are seeing red flags of...
01:14 , Oct 6, 2018 |  BioCentury  |  Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18 saw investors...
18:32 , Sep 7, 2018 |  BC Week In Review  |  Company News

Osaka University grants Otsuka rights to MMG49

Osaka University (Osaka, Japan) granted Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) exclusive, worldwide rights to patents associated with MMG49, a CAR T cell therapy that targets the active conformer of integrin β(7). The university will...
17:56 , Sep 7, 2018 |  BC Week In Review  |  Company News

Letter prompts new manufacturing concerns for Fosun

A second manufacturing scandal in as many weeks involving alleged falsification of manufacturing records drove down shares of Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196) on Aug. 31. According to media reports, self-identified employees...
17:44 , Sep 7, 2018 |  BC Week In Review  |  Company News

Alkermes in pay-for-performance deal

Alkermes plc (NASDAQ:ALKS) signed a contract with UPMC Health Plan for opioid antagonist Vivitrol naltrexone that links reimbursement of the drug to positive clinical outcomes when treating opioid dependence. Alkermes spokesperson Matthew Henson did not...